Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
Global Heart · 20.11.2023 · 18 (1)
DOI: 10.5334/gh.1275 ↗Kurz gefasst
Editorial in der Zeitschrift Global Heart, erschienen am 20.11.2023. Verfasst von Marianna Fontana und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. Hauptthemen laut MEDLINE: Amyloidosis, Heart Failure, Cardiomyopathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
Transthyretin cardiac amyloidosis (ATTR-CA) has been traditionally considered a rare and inexorably fatal condition. ATTR-CA now is an increasingly recognised cause of heart failure and mortality worldwide with effective pharmacological treatments. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have transformed the diagnosis of ATTR-CA, which is now possible without recourse to endomyocardial biopsy in around 70% of cases. Many patients are now diagnosed at an earlier stage. Echocardiography and cardiac magnetic resonance have enabled identification of patients with possible ATTR-CA and more accurate prognostic stratification. Therapies able to slow or halt ATTR-CA progression and increase survival are now available and there is also evidence that patients may benefit from specific conventional heart failure medications. A wide horizon of possibilities is unfolding and awaits discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.
- Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste 34149, IT.
- European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Europe.
ORCID-Profile: Marianna Fontana, Aldostefano Porcari, Philip N Hawkins
Förderung
- British Heart Foundation
Zitieren
APA
Fontana, M., Porcari, A., & Hawkins, P. N. (2023). Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy. Global Heart, 18(1). https://doi.org/10.5334/gh.1275
Vancouver
Fontana M, Porcari A, Hawkins PN. Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy. Global Heart. 2023;18(1). doi:10.5334/gh.1275
BibTeX
@article{Fontana2023,
author = {Fontana, Marianna and Porcari, Aldostefano and Hawkins, Philip N},
title = {Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy},
journal = {Global Heart},
year = {2023},
volume = {18},
number = {1},
doi = {10.5334/gh.1275}
}
EUVIMED